Tan Jie, Gong Enying, Gallis John A, Sun Shifeng, Chen Xingxing, Turner Elizabeth L, Luo Siran, Duan Jingying, Li Zixiao, Wang Yilong, Yang Bolu, Lu Shiyu, Tang Shenglan, Bettger Janet P, Oldenburg Brian, Miranda J Jaime, Karmacharya Biraj, Kinra Sanjay, Shao Ruitai, Ebrahim Shah, Yan Lijing L
School of Public Health, Wuhan University, Wuhan, China.
Global Health Research Center, Duke Kunshan University, Kunshan, China.
JAMA Netw Open. 2024 Dec 2;7(12):e2449561. doi: 10.1001/jamanetworkopen.2024.49561.
Despite evidence of the short-term benefits of multicomponent primary care-based interventions, their long-term effects are unproven.
To evaluate the long-term outcomes of a system-integrated technology-enabled model of care (SINEMA intervention) for stroke management for systolic blood pressure (BP) and other outcomes among patients with stroke in China.
DESIGN, SETTING, AND PARTICIPANTS: This long-term follow-up included community-dwelling clinically stable surviving participants with stroke in an open-label cluster randomized clinical trial. Of 218 villages from Nanhe County in Hebei, China, an area with suboptimal health care resources and stroke prevalence doubling the national average, 50 villages (clusters) were recruited between June 23 and July 29, 2017, and randomized in a 1:1 ratio to an intervention or a control arm (usual care). The intervention lasted 1 year (to July 31, 2018), with a posttrial observational follow-up conducted from October 1, 2022, to August 27, 2023.
Village doctors were provided with training, performance-based incentives, technical support, and customized mobile health tools to deliver monthly follow-up to patients. Patients also received daily voice messages emphasizing medication adherence and physical activity. No intervention was requested or supported during the posttrial period.
Between-arm differences in intention-to-treat analyses of individual-level changes from baseline to long-term posttrial in systolic BP (primary outcome) and stroke recurrence, diastolic BP, BP control, antihypertensive medication use and regimen adherence, and disability (secondary outcomes).
Among a total of 1042 stroke survivors, 44 (4.2%) were lost to follow-up and 998 (mean [SD] age at baseline: 65.0 [8.2] years; 544 [54.4%] men) completed posttrial assessment at a mean (SD) period of 66.6 (3.7) months (5.5 years) after baseline. The multicomponent intervention was associated with an estimated between-arm net reduction in systolic BP of -2.8 (95% CI, -5.3 to -0.3) mm Hg (P = .03). Most secondary outcomes showed a tendency toward lasting effects, with a notable absolute net reduction of 6.0 (95% CI, -11.3 to -0.7) percentage points and risk ratio of 0.77 (95% CI, 0.61-0.99) for stroke recurrence. In subgroup analyses, significant between-arm differences were observed among women and people with lower educational attainment, lower income, and higher use of and adherence to medications.
In this long-term follow-up of a cluster randomized clinical trial, the 1-year intervention was associated with significantly reduced systolic BP and stroke recurrence at 5.5 years, providing evidence of long-term health and inequity-reducing benefits and holding promise for scaling up of the intervention in resource-limited settings.
ClinicalTrials.gov Identifier: NCT05792618.
尽管有证据表明基于多组分初级保健的干预措施具有短期益处,但其长期效果尚未得到证实。
评估一种系统整合的、基于技术的护理模式(SINEMA干预)对中国卒中患者收缩压(BP)及其他结局的长期影响。
设计、设置和参与者:这项长期随访纳入了一项开放标签整群随机临床试验中社区居住的临床稳定的卒中存活参与者。在中国河北省南和县的218个村庄中,该地区医疗资源欠佳且卒中患病率是全国平均水平的两倍,于2017年6月23日至7月29日招募了50个村庄(群组),并按1:1的比例随机分为干预组或对照组(常规护理)。干预持续1年(至2018年7月31日),并于2022年10月1日至2023年8月27日进行试验后观察性随访。
为乡村医生提供培训、基于绩效的激励措施、技术支持和定制的移动健康工具,以便每月对患者进行随访。患者还会收到强调药物依从性和身体活动的每日语音信息。试验后期间不要求或支持任何干预措施。
在从基线到试验后长期的个体水平变化的意向性分析中,收缩压(主要结局)、卒中复发、舒张压、血压控制、降压药物使用和方案依从性以及残疾(次要结局)的组间差异。
在总共1042名卒中幸存者中,44名(4.2%)失访,998名(基线时平均[标准差]年龄:65.0[8.2]岁;544名[54.4%]为男性)在基线后平均(标准差)66.6(3.7)个月(5.5年)时完成试验后评估。多组分干预与收缩压组间估计净降低-2.8(95%CI,-5.3至-0.3)mmHg相关(P = 0.03)。大多数次要结局显示出持续效应的趋势,卒中复发的绝对净降低显著为6.0(95%CI,-11.3至-0.7)个百分点,风险比为0.77(95%CI,0.61 - 0.99)。在亚组分析中,在女性以及教育程度较低、收入较低、药物使用和依从性较高的人群中观察到显著的组间差异。
在这项整群随机临床试验的长期随访中,1年的干预与5.5年时收缩压显著降低和卒中复发减少相关,为长期健康和减少不平等效益提供了证据,并有望在资源有限的环境中扩大干预规模。
ClinicalTrials.gov标识符:NCT05792618。